Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

18.45USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$18.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
250,754
52-wk High
$36.80
52-wk Low
$16.00

Select another date:

Thu, Aug 31 2017

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40

* Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update

BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia

* Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia

BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies

* Says announces commercial availability of intrarosa (prasterone) at U.S. pharmacies

BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena

* Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

BRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals

* Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing Source text (http://bit.ly/2rj6Y6h) Further company coverage:

BRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln

* Amag Pharmaceuticals announces pricing of $300 million of 3.25% convertible senior notes due 2022

BRIEF-AMAG Pharma announces proposed offering of $250 mln of convertible senior notes due 2022

* AMAG Pharmaceuticals Inc announces proposed offering of $250 million of convertible senior notes due 2022

BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study

* Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study

BRIEF-AMAG Pharmaceuticals posts Q1 loss per share $1.06

* AMAG Pharmaceuticals announces first quarter 2017 financial results and provides corporate update

Select another date: